Macroaxis considers Loxo Oncology to be not too risky. Loxo Oncology
has Sharpe Ratio of -0.0374 which conveys that Loxo Oncology
had -0.0374% of return per unit of risk over the last 1 month. Macroaxis philosophy towards estimating risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators
. Loxo Oncology exposes twenty-eight different technical indicators
which can help you to evaluate volatility that cannot be diversified away. Please be advised to verify Loxo Oncology Mean Deviation
of 1.64 and Risk Adjusted Performance
of 0.00636 to check out risk estimate we provide. Macroaxis gives Loxo Oncology performance score of 0 on a scale of 0 to 100. The company secures Beta (Market Risk) of -0.0978 which conveys that as returns on market increase, returns on owning Loxo Oncology are expected to decrease at a much smaller rate. During bear market, Loxo Oncology is likely to outperform the market.. Even though it is essential to pay attention to Loxo Oncology price patterns, it is always good to be careful when utilizing equity historical price patterns. Macroaxis philosophy towards estimating future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Loxo Oncology exposes twenty-eight different technical indicators which can help you to evaluate its performance. Loxo Oncology has expected return of -0.082%. Please be advised to verify Loxo Oncology Treynor Ratio, Expected Short fall as well as the relationship between Expected Short fall and Day Median Price to decide if Loxo Oncology past performance will be repeated at some point in the near future.
|15 days auto-correlation||(0.46) |
Modest reverse predictability
Loxo Oncology has modest reverse predictability. Overlapping area represents the amount of predictability between Loxo Oncology time series from August 21, 2018 to September 5, 2018 and September 5, 2018 to September 20, 2018. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Loxo Oncology price movement. The serial correlation of -0.46 indicates that about 46.0% of current Loxo Oncology price fluctuation can be explain by its past prices. Given that Loxo Oncology has negative autocorrelation for selected time horizon, investors may consider taking a contrarian position regarding future price movement of Loxo Oncology for similar time interval.
|Spearman Rank Test||-0.66|